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Chlamydia trachomatis (Ct) comprises distinct sero-
groups and serovars. The present study evaluates a
novel Ct amplification, detection, and genotyping
method (Ct-DT assay). The Ct-DT amplification step is
a multiplex broad-spectrum PCR for the cryptic plas-
mid and the VD2-region of ompl. The Ct-DT detection
step involves a DNA enzyme immunoassay (DEIA)
using probes for serogroups (group B, C, and inter-
mediate) and the cryptic plasmid, permitting sensi-
tive detection of 19 Ct serovars (A, B/Ba, C, D/Da, E,
F, G/Ga, H, I/Ia, J , K, L1, L2/L2a, and L3) without any
cross-reactivity with other Chlamydia species and
pathogenic bacteria or commensal organisms of the
genital tract. Ct-positive samples are analyzed by a
nitrocellulose-based reverse hybridization assay
(RHA) containing probes for the 19 different serovars
and for the cryptic plasmid. The sensitivity of the
PCR-DEIA on clinical specimen is equivalent to that of
the Cobas TaqMan assay [  0.95 (95% confidence
interval  0.92 to 0.99)]. Using the RHA, 98% of the
Ct-DT detection step-positive samples could be typed.
Analysis of cervical swabs from Uganda and The Neth-
erlands revealed that the most common serovars in
Uganda are G/Ga (45%), E (21%), K (13%), and F
(8%), and in The Netherlands serovars E (38%), F
(23%), G/Ga (11%), andD/Da (7%)weremost common.
Thus, multiplex broad-spectrum PCR in combination
with DEIA and RHA permits highly sensitive and spe-
cific detection and identification of Ct serovars. (J Mol
Diagn 2007, 9:631–638; DOI: 10.2353/jmoldx.2007.070011)
Chlamydia trachomatis (Ct) is the most prevalent sexually
transmitted bacterial pathogen. Annually, approximately
90 million new cases occur worldwide.1,2 Most infections
remain asymptomatic, but when left untreated, these in-
fections can lead to pelvic inflammatory disease, ectopic
pregnancy, and tubal infertility.3 C. trachomatis is also
responsible for chronic keratoconjunctivitis (trachoma)
that can cause blindness.4,5 As a species, C. trachomatis
can be further divided into three serogroups, and subse-
quently into 19 serovars, including the five genovariants
Ba, Da, Ia, Ga, and L2a.
Serovar identification is based on differences in the
amino acid sequence of the major outer membrane pro-
tein (MOMP). Serovars were initially distinguished by
culture of the strain and subsequent identification by
monoclonal antibodies.6,7 The three main phylogenetic
branches within the omp1 gene (encoding MOMP) rep-
resent serogroups B, C, and the intermediate group. The
serogroup B complex comprises serovars B/Ba, D/Da, E,
L1, and L2/L2a. The serogroup C complex contains se-
rovars A, C, H, I/Ia, J, K, and L3; and the intermediate
group contains serovars F and G/Ga.
The different serovars of C. trachomatis display diverse
biological activities. Serovars A, B/Ba, and C are com-
monly associated with an ocular disease, trachoma.8 Se-
rovars D/Da, E, F, G/Ga, H, I/Ia, J, and K are common in
the urogenital tract and can sometimes be detected in
the respiratory tract of infants,9 whereas serovars B and
C are rarely detected in the urogenital tract.10 The sero-
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vars L1, L2/L2a, and L3 are mainly detected in the ingui-
nal lymph nodes and the rectum and may cause lympho-
granuloma venereum.11
C. trachomatis infection may also be a cofactor for an
enhanced risk for the development of cervical can-
cer.12,13 The primary cause of cervical cancer is persis-
tent infection with high-risk human papillomavirus, but C.
trachomatis may also play a role in this process. Human
papillomavirus and C. trachomatis are the most common
sexually transmitted infections of the cervix and are often
co-transmitted.14
Because C. trachomatis serovars may be associated
with diverse clinical manifestations and little is known
about the epidemiology of the different serovars, there
is a clear need for accurate and efficient genotyping
tools.2 Laboratory diagnosis of C. trachomatis infection
is routinely performed by molecular methods such as
PCR or liquid hybridization. Most assays aim at detec-
tion of the cryptic plasmid [Cobas TaqMan (Roche
Diagnostics, Indianapolis, IN); Hybrid Capture 2 (Di-
gene Corporation, Gaithersburg, MD)]1,15 or ribosomal
RNA genes [Pace 2 System (Gen-Probe Corporation,
San Diego, CA)]. These commercial assays detect the
presence of C. trachomatis but cannot differentiate be-
tween the different serovars. Serotype identification
based on the omp1 gene can be performed by DNA
sequencing,16 by restriction fragment length polymor-
phism,17 or by reverse hybridization.2,15 The aim of the
present study was to evaluate a novel Ct amplification,
detection, and genotyping system (Ct-DT assay),
which combines sensitive detection of C. trachomatis
infection by a multiplex broad-spectrum PCR and mi-
crotiterplate hybridization, targeting at the cryptic
plasmid and the omp1 with the possibility to identify
C. trachomatis serovars in positive samples by reverse
hybridization, using the same amplicons.
Materials and Methods
Reference Strains
Cultured Chlamydia strains representing 14 different se-
rovars (A/Sa-1, B/TW-5, C/UW-1, D/IC-CAL-8, E/DK-20,
F/MRC-301, G/IOL-238, H/UW-4, I/UW-12, J/UW-36,
K/UW-31, L1/440-L, L2/434-B, and L3/404-L), Chlamy-
dophila psittaci isolate 6BC, Chlamydophila pneumoniae
isolate TW183, and Chlamydia muridarum isolate MoPn
were obtained from the Reinier de Graaf Hospital and the
VU University Medical Center and grown/isolated as de-
scribed previously.18 The serovar of each of the C. tra-
chomatis isolates was confirmed by sequencing of the
VD2 fragment of the omp1 gene. The most relevant non-
Chlamydia pathogenic bacteria present in the genital tract
used for specificity analysis of the multiplex broad-spec-
trum PCR are Enterococcus faecalis, Escherichia coli,
Gardnerella vaginalis, Klebsiella pneumoniae, Neisseria
gonorrhoeae, Pseudomonas aeruginosa, Streptococcus
pyogenes, and Staphylococcus aureus.
Clinical Specimens
Cervical swab specimens were obtained from women
attending the gynecology outpatient clinic of the Reinier
de Graaf Hospital. Based on the initial diagnosis by an
in-house PCR assay, 99 consecutive C. trachomatis-pos-
itive samples were selected. In addition, 191 ThinPrep
cervical swab samples were obtained from women at-
tending a primary health care center in Kampala,
Uganda, between January 2003 and May 2005. Cervical
swabs were used to obtain cervical cells, which were
resuspended in PBS (Delft) or PreservCyt (Uganda).
DNA Isolation
DNA isolation from the cultured strains was performed
with the QIAamp DNA mini kit (Qiagen GmbH, Hilden,
Germany), including overnight pretreatment with protein-
ase K.
DNA from the clinical specimens was isolated from 200
l of cervical cell suspension using the MagnaPure LC
Isolation instrument and the Total Nucleic Acid isolation
kit as described by the manufacturer (Roche Applied
Science, Indianapolis, IN). Isolated DNA was resus-
pended in a final volume of 100 l of dilution buffer, and
10 l was used for each PCR sample (Primus HT
multiblock thermal cycler; MWG-Biotech AG, Ebersberg,
Germany).
C. trachomatis Sequences from GenBank
C. trachomatis omp1 sequences were obtained from Gen-
Bank (http://www.ncbi.nlm.nih.gov/Genbank/index.html)
and were used for the selection of the primers and
probes. The GenBank numbers used for primer/probe
selection were: Serovar A, M58938; Serovar B/Ba,
AF063194, AF304856, AY535080, AY378287, and
DQ064281; Serovar C, AF352789 and AY380118; Sero-
var D/Da, AY535092, AY535093, AF063196, AY535090,
AY535087, AY535094, AY535089, AY535095, and
AY535091; Serovar E, AY535111, U78528, AY535100,
U78532, AY535106, AY535104, AY535099, U78536,
AY535107, and AY535109; Serovar F, AY535118,
AY535123, AY535120, AY535121, and AY535124; Sero-
var G, AY535136, AY535131, AY535127, and AY535134;
Serovar H, AY535137 and AY464146; Serovar I/Ia,
AY535152, AF202456, AY535139, AY535140, AY535144,
AY535148, and AY535150; Serovar J/Ja, AY535156,
AY535161, AY535165, AY535157, AY535162, and
AY535166; Serovar K, AY535172, AY535167, AY535168,
AY535169, and AY535170; Serovar L1, L35606 and
M36533; Serovar L2/L2a, AF304858, DQ064295, and
DQ217607; and Serovar L3, X55700.
C. trachomatis Amplification Step
From the Ct-DT assay (Labo Biomedical Products BV,
Rijswijk, The Netherlands), the amplification step com-
prises a Ct-multiplex-broad-spectrum PCR primer mix
with multiple forward and reverse primers, targeting re-
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gions A and E, as shown in Figure 1 and generating a
biotinylated amplicon of 157 to 160 bp from the omp1
VD2 region (Figure 1, region D). The following forward
(fw) and reverse (rv) primers are included in the primer
mix: momp-fw1bio, 5-TTCAATTTAGTTGGATTGTTTGG-
3; momp-fw2bio, 5-TCAACTTAGTTGGITTATTCGG-3;
momp-fw3bio, 5-TCAATTTAGTGGGGTTATTCGG-3;
momp-rv1bio, biotin-5-CACATTCCCAGAGAGCTGC-3;
momp-rv2bio, biotin-5-CACATTCCCACAAAGCTGC-3;
momp-rv3bio, biotin-5-CGGACTCCCACAAAGCTGC-3;
and momp-rv4bio, biotin-5-GCACTCCCACAAAGCTGC-
3. The primer mix also contains the following primers to
generate a 241-bp amplicon from the cryptic plasmid:
KL1, 5-TCCGGAGCGAGTTACGAAGA-3; and KL2-bio,
biotin-5-AATCAATGCCCGGGATTGGT-3.19
The PCR mix consisted of 10 l of isolated DNA, 2.5
mmol/L MgCl2, 1 GeneAmp PCR Buffer II, 1.5 U of
AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA), 0.2 mmol/L deoxynucleoside triphos-
phates (Invitrogen, Carlsbad, CA), and 15 pmol of each
primer (Eurogentec S.A., Seraing, Belgium) in a total
volume of 50 l. The standard PCR program involves a
9-minute preheating step at 94°C followed by 40 cycles
of amplification (30 seconds at 94°C, 45 seconds at
55°C, and 45 seconds at 72°C) and a final 5-minute
elongation step at 72°C.
Gel Electrophoresis
Gel electrophoresis was performed on 3% agarose gels
for 225 to 300 volt-hours in 0.5 Tris borate-EDTA buffer.
Sequence Analysis
Amplified DNA fragments were excised from the 3%
Tris-borate-EDTA agarose gels and purified with the
QIAquick gel extraction kit (Qiagen). Purified ampli-
cons were directly sequenced using the Big Dye Ter-
minator Cycle Sequencing kit (Applied Biosystems).
The sequenced products were subsequently analyzed
using the ABI 3100-Avant Genetic Analyzer (Applied
Biosystems). The resulting DNA sequences were ana-
lyzed with the Vector NTI Advance 9.0 software (In-
vitrogen) and compared with C. trachomatis serovars
present in GenBank using the BLAST software
(http://www.ncbi.nlm.nih.gov/BLAST/).20
C. trachomatis Detection Step
The Ct detection step from the Ct-DT assay comprises a
DNA enzyme immunoassay (DEIA) with a mix of con-
served probes. As the first step in the analysis of C.
trachomatis, PCR products were hybridized to a mixture
of probes for the cryptic plasmid and the omp1 gene
(Figure 1, region C) in a DEIA.21 This assay permits
general detection of the presence of C. trachomatis DNA
in a clinical sample. Briefly, the biotinylated PCR prod-
ucts are captured onto streptavidin-coated microtiter
plates and denatured by the addition of NaOH. Uncap-
tured DNA strands are removed by washing. A mix of one
digoxigenin-labeled cryptic plasmid probe and four
digoxigenin-labeled serogroup probes were added and
hybridized to the captured strand of the PCR product.
After washing, the hybrids are detected by an enzymatic
reaction, resulting in a colored product. The optical den-
sity at 450 nm is measured in each well and evaluated by
comparison with titrated positive, borderline positive, and
negative controls included in each DEIA run.
Cobas TaqMan Ct Testing
The Cobas TaqMan Ct test (Roche Molecular Systems,
Branchburg, NJ) was performed exactly according to the
manufacturer’s instructions. The test to detect C. tracho-
matis in clinical samples is run on the Roche Diagnostics
Cobas TaqMan 48 Analyzer, an instrument that offers
automated real-time PCR amplification and detection in a
closed system. The Cobas TaqMan 48 Analyzer can
process up to 48 tests per cycle and provide results in
2.5 hours after sample preparation. Systematic internal
controls and built-in cross-contamination prevention fur-
ther enhance reliability of results.
C. trachomatis Genotyping Step
The Ct genotyping step from the Ct-DT assay is based on
the reverse hybridization assay (RHA) methodology,22
Figure 1. Alignment of the 157- to 160-bp target sequences from the VD2 omp1 gene, which are amplified by the Ct-amplification step, generating region D.
Regions A and E are the targets for forward and reverse primers, respectively. The interprimer region (B) is used as target for serovar-specific probes.
Serogroup-specific probes are aimed at region C. The reference sequences that were used for this alignment are as follows: Serovar A, M58938; Serovar B,
DQ064281; Serovar C, AF352789; Serovar D, AF063196; Serovar E, AY535104; Serovar F, AY535123; Serovar G, AY535136; Serovar H, AY535137; Serovar Ia,
AY535150; Serovar J, AY535161; Serovar K, AY535167; Serovar L1, M36533; Serovar L2, DQ064295; and Serovar L3, X55700.
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allowing the simultaneous identification of multiple C. tra-
chomatis serovars in a single hybridization step. This
assay is based on the serovar-specific sequence heter-
ogeneity in the VD2 region of the omp1 gene (Figure 1)
permitting the development of specific probes for the
three serogroups (B, C, and intermediate), 14 different
serovars (the differentiation between B and Ba, D and Da,
G and Ga, I and Ia, and L2 and L2a is not possible), and
the cryptic plasmid.
The RHA kit, containing the strips and all assay re-
agents, was used according to the manufacturer’s in-
structions. Briefly, 10 l of the biotin-labeled multiplex
PCR product was mixed with 10 l of denaturation solu-
tion in a plastic trough containing the Ct strip. The mix
was incubated for 5 minutes at room temperature. Pre-
heated (37°C) hybridization buffer was added and incu-
bated at 50°C for 1 hour. All incubations and washing
steps were performed automatically in an AutoLiPA in-
strument (Tecan Austria GmbH, Salzburg, Austria). The
strips were washed twice for 30 seconds and once for 30
minutes at 50°C with wash solution (3 SSC and 0.1%
SDS). After this wash, the strips were incubated with
alkaline phosphatase-streptavidin conjugate for 30 min-
utes at room temperature. Strips were washed twice with
rinse solution and once with substrate buffer. Substrate
(5-bromo-4-chloro-3-indolylphosphate and nitroblue tet-
razolium) was added and incubated for 30 minutes at
room temperature, generating a purple precipitate on the
location of hybrid formation. The reaction was stopped by
washing for 3 and 10 minutes with rinse solution and by a
wash with water. The strips were dried, and the signals
were visually interpreted.
Most of the C. trachomatis serovars are recognized by
hybridization to one of the serogroup probes and to a
serovar-specific probe. The outline of the RHA strip and
representative examples of C. trachomatis serovars are
shown in Figure 2. The top line (conjugate control) con-
tains a positive control of biotinylated DNA. Because the
C. trachomatis serovars often differ by only a few nucle-
otides in the interprimer sequences, well-controlled hy-
bridization conditions are required.
An additional probe was included for a genovariant of
serovar J (designated J*). This probe also reacts with
serovar L3. For this specific genovariant, pattern recog-
nition was used. The genovariant J* was present if probe
J*/L3 was positive and the probe for L3 negative. Con-
sequently, in mixed infections of serovar L3 and J*, the
serovar J* cannot be identified.
Results
Sensitivity and Specificity of Ct-DT Assay
Compared with the Cobas TaqMan
Several 10-fold limiting dilution series of the DNA from C.
trachomatis L1 serovars were tested by the multiplex
PCR, followed by agarose gel electrophoresis and the
DEIA. The same DNA samples were also subjected to
analysis by the Cobas TaqMan assay. The exact copy
number of C. trachomatis DNA in the dilutions was not
known. Analysis on an agarose gel showed that the lower
border of detection of the cryptic plasmid in the 10-fold
dilution series was similar as for the omp1 gene (Figure
3A). The Ct-DT detection step (DEIA) and the Cobas
TaqMan Ct Test were equal in detection of C. trachomatis
DNA (Figure 3B) with a sensitivity of 20 copies (according
the Manufacturer’s instruction). The Ct-DT assay was
able to detect DNA from all strains representing 14 dif-
ferent serovars (A, B, C, D, E, F, G, H, I, J, K, L1, L2, and
L3). No amplicons were generated from DNA of Chlamy-
dophila psittaci, Chlamydophila pneumoniae, and Chla-
mydia muridarum or from the bacterial isolates E. faecalis,
E. coli, G. vaginalis, K. pneumoniae, N. gonorrhoeae, P.
aeruginosa, S. pyogenes, and S. aureus.
Accuracy of Ct-DT Assay in Comparison with
the Cobas TaqMan Ct Test in Clinical Specimen
The accuracy of the multiplex PCR-DEIA Ct assay was
assessed by testing 290 clinical samples in parallel with
the Cobas TaqMan Ct Test. Results are presented in
Table 1. Of the 191 samples from Uganda, 51 samples
were positive and 135 samples were negative in both
assays. Three samples were DEIA negative but COBAS
TaqMan positive, and vice versa, two samples were DEIA
positive but Cobas TaqMan negative [  0.94 (95%
confidence interval 0.88 to 0.99)].
The 99 C. trachomatis-positive samples (as initially de-
termined by an in-house PCR-DEIA) from The Nether-
lands were all confirmed positive with the new multiplex
PCR-DEIA test. Two samples remained negative by Co-
bas TaqMan but were positive with the multiplex PCR-
DEIA. Combining both groups (Table 1), 148 samples
(51%) were positive, and 135 (47%) samples were neg-
ative with both tests. Four samples (1%) were Cobas
TaqMan negative but multiplex PCR-DEIA positive, and
Figure 2. Outline and representative example of the RHA C. trachomatis
genotyping step. The positions of the control line and the 19 specific probes
for the cryptic plasmid, three different serogroups, and 15 serovars are shown
at the left. The letter above each strip indicates the Ct serovar for which DNA
was amplified by the multiplex broad spectrum PCR. The exact interpretation
of hybrid patterns is described in Materials and Methods. J* was found as a
clinical isolate.
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three samples (1%) were multiplex PCR-DEIA negative
but Cobas TaqMan positive [  0.95, (95% confidence
interval 0.92 to 0.99)].
Analytical Specificity of the Ct-DT Genotyping
Step
The outline and representative examples of the Ct-geno-
typing step of Ct-DT assay are shown in Figure 2. The
strip comprises a conjugate control line (biotinylated
DNA), a probe for the cryptic plasmid, and a series of
omp1 probes. The omp1 probes comprise three C. tra-
chomatis serogroup-specific probes and 15 serovar-spe-
cific probes representing all of the known serovars. For
serovar J, an additional probe was added to detect a
genovariant, designated as J*.
Hybridization with amplicons from the 15 different se-
rovar reference isolates (14 serovars and one genovari-
ant) revealed no cross-reaction, and all of the serovar
probes were highly specific. The serogroup probes also
identified the correct serogroup for each of the reference
serovars. The cryptic plasmid probe identified all of the
different reference serovars.
Analytical Sensitivity of the Ct-DT Genotyping
Step
The same multiplex PCR amplicons analyzed by agarose
gel electrophoresis and DEIA were also characterized by
the RHA method. Figure 3C shows that the RHA test of
the 103 dilution was positive for the cryptic plasmid but
remained negative for the serovar probes, whereas the
104 dilution showed the opposite results. These results
reflect sampling variations that may occur around the
border of detection, when only a few copies of the target
sequence are present. This phenomenon was observed
several times in testing dilution series around the border
of detection (data not shown).
Typing of C. trachomatis-Positive Cervical
Swabs
Of the 152 clinical samples that were positive for C.
trachomatis by the DEIA, 149 were further analyzed by
reverse hybridization. In 147 of the 149 samples (99%),
the cryptic plasmid and the serogroup and serovar could
be determined (Tables 2 and 3). In two (1%) of the 149
samples, only the cryptic plasmid was detected by the
RHA (Figure 4, lane 7). The results are summarized in
Tables 2 and 3. Of the 147 serogroup-positive samples,
141 (96%) contain a single Ct infection (Table 2). Only 6
samples (4%) contain multiple C. trachomatis serovars.
The intermediate serogroup (containing serovars F
and G) is the most prevalent serogroup (41% as a single
infection and 3% as a multiple infection), followed by
serogroup B (39% as a single infection and 4% as a
multiple infection). Serogroup C was detected in only 27
Figure 3. Limiting dilution series of C. trachomatis DNA, analyzed for the
presence of the plasmid and the omp1 gene. A: Agarose gel (3%) showing
amplicons from the dilution series of Ct serovar L1. B: DEIA and Cobas
TaqMan results. The Cobas TaqMan internal control shows no inhibition. C:
RHA results of the corresponding amplicons, which agree with the results of
the agarose gel.
Table 1. C. trachomatis Detection Results of a Panel of 290 Cervical Swabs from Uganda and the Netherlands Tested with Both
the Cobas TaqMan and the Multiplex PCR-DEIA Ct-Detection Step (Ct-DT Assay)
Cobas TaqMan
The Netherlands (n  99) Uganda (n  191)
Total
Total (n  290)
Positive Negative Positive Negative Positive Negative
Multiplex PCR- DEIA Positive 97 2 51 2 152 148 4
Negative 0 0 3 135 138 3 135
Total 97 2 54 137 290 151 139
Not determined   0.93 (95% confidence
interval  0.88 to 0.99)
  0.95 (95% confidence
interval  0.92 to 0.99)
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samples (16% in a single infection and 2% as a multiple
infection). Overall, the most prevalent serovar was sero-
var E (32%; serogroup B), followed by serovars G/Ga
(23%; intermediate serogroup) and F (18%; intermediate
serogroup), as shown in Table 3. Serovars D/Da, H, I/Ia,
J, and K were infrequently observed.
In seven samples, reactivity to serovar H and K probes
(both serogroup C) was observed (Figure 4, lanes 12 and
14). Sequence analysis of the whole omp1 gene from
these seven cases revealed the presence of a sequence
closely matching serovar K, which also contained a mu-
tation resulting in a match with the probe for serovar H
(data not shown). Therefore, this sequence was desig-
nated K*.
The distribution of the serovars and serogroups (Ta-
bles 2 and 3) showed a clear difference between sam-
ples from Uganda and The Netherlands. In both coun-
tries, the same percentage of multiple infections (4%) is
observed. The most common serovars detected in the
Uganda samples were serovar G/Ga (45%), serovar E
(21%), K (13%), and F (8%), whereas in The Netherlands,
serovar E (38%) was the most prevalent one followed by
F (23%), G/Ga (11%), and D/Da (7%). The prevalence of
serovars E, F, and G/Ga is significant different between
The Netherlands and Uganda.
Genovariant K* was detected in seven samples from
Uganda but was not present in samples from The Neth-
erlands. In these cervical samples, serovars A, B, C, L1,
L2/L2a, and L3 were not detected.
Discussion
The aim of the present study was to evaluate the novel
Ct-DT assay, which combines sensitive detection of C.
trachomatis infection with the possibility to identify all
different C. trachomatis serovars, using the same ampli-
cons of a multiplex PCR. The advantage of this multiplex
PCR is that both the cryptic plasmid and the omp1 gene
targets can be detected independently, revealing an in-
crease in sensitivity to detect C. trachomatis.
Analysis of clinical samples showed that the novel
detection method has the same sensitivity as the Cobas
TaqMan PCR system, which is based on the cryptic
plasmid only. The sensitivity of the Cobas TaqMan has
been determined on 20 copies of the cryptic plasmid
(manufacturer’s instructions; Roche Molecular Systems).
In clinical samples and in the 10-fold dilution series, the
same sensitivity could be obtained.
Table 2. C. trachomatis Serogroup Distribution in Positive Samples from The Netherlands and Uganda as Determined by the Ct
Genotyping Step
Infection type
Serogroups detected in clinical samples
Serogroup The Netherlands n (%) Uganda n (%) Total n (%)
Single infection 90 (96) 51 (96) 141 (96)
B 43 (46) 14 (26) 57 (39)
C 15 (16) 9 (17) 24 (16)
Intermediate 32 (34) 28 (53) 60 (41)
Multiple infection 4 (4) 2 (4) 6 (4)
B, C, and Intermediate 2 (2) 0 2 (1)
B and C 1 (1) 0 1 (1)
B and Intermediate 1 (1) 2 (4) 3 (2)
Total 94 (100) 53 (100) 147 (100)
Table 3. Distribution of C. trachomatis Serovars in Samples from The Netherlands and Uganda, as Determined by the RHA Ct
Genotyping Step
Infection type
Serovars detected in the clinical samples
Serovar The Netherlands n (%) Uganda n (%) Overall n (%)
Single infection 90 (96) 51 (96) 141 (96)
D/Da 7 (7) 3 (6) 10 (7)
E 36 (38) 11 (21) 47 (32)
F 22 (23) 4 (8) 26 (18)
G/Ga 10 (11) 24 (45) 34 (23)
H 2 (2) 0 2 (1)
I/Ia 1 (1) 1 (2) 2 (1)
J 5 (5) 1 (2) 6 (4)
K 7 (7) 0 7 (5)
K* 0 7 (13) 7 (5)
Multiple infection 4 (4) 2 (4) 6 (4)
E, F, I/Ia 2 (2) 0 2 (1)
E, F 1 (1) 1 (2) 2 (1)
E, G/Ga 0 1 (2) 1 (1)
E, I/Ia 1 (1) 0 1 (1)
Total 94 (100) 53 (100) 147 (100)
Ct-DT assay H and K dual-positive samples were sequenced. K* is the result of sequence analysis of the whole omp1 gene.
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Recently, a new variant strain has been isolated in
Sweden with a 377-bp deletion in the cryptic plasmid,
compromising several commercially available PCR-
based systems.23 The PCR included in the present Ct-DT
amplification step is aimed at another region of the cryp-
tic plasmid and will therefore be able to also detect the
new variant. Further analysis by RHA genotyping on the
four Ct-DT-positive/Cobas-negative samples revealed
that all contained the endogenous plasmid. Sequence
analysis should be done to determine whether a deletion
is present.
However, results from the serial dilutions of C. tracho-
matis DNA showed that around the limit of detection, the
assay may show positivity for either the cryptic plasmid or
the omp1 gene. This clearly reflects the effect of sampling
variation as might be observed in the discrepant samples
(Table 1). This may play an important role when input
samples contain a very low number of target molecules or
when using nonhomogeneous clinical materials, such as
cervical swabs or biopsy specimens. Some studies de-
tected plasmid-free C. trachomatis strains.24–26 However,
sampling variations such as observed in the dilution se-
ries may increase the possibility of finding apparent plas-
mid-negative strains. The disadvantage of a single target
PCR-based test like the Cobas TaqMan can result in false
negativity, which will be minimized by the novel multiplex
PCR DEIA system that recognizes both the cryptic plas-
mid and the omp1 gene targets.
Serotype identification by analysis of the MOMP gene
can be achieved by DNA sequencing,16 by restriction
fragment length polymorphism,17 or by reverse hybrid-
ization.2,15 The use of large fragments for RLFP (lower
sensitivity), nucleotide sequencing (detection of mixed
infections), or a nested PCR system for the described
RHA methods (introduction of contamination) is not opti-
mally suited for routine diagnostics.
In the cervical material derived from Uganda, the most
commonly detected serovar was serovar G/Ga (45%),
followed by serovar E (21%). In the cervical swabs de-
rived from The Netherlands, serovars E (38%) and F
(23%) were the most common. The high prevalence of
serovars E and F is in agreement with other studies. In
Australia, the most common serovars were E (41%) and F
(26%).2 In Sweden, serovar E (47%) was the most com-
mon, followed by serovar F (17%); and in Thailand, sero-
vars F (25%) and D (22.6%) were the most commonly
identified.27,28 In Colombia the most common serovars
identified were serovars D (22.2%), F (18.5%), and G
(13.6%).15 Serovars D, E, F, and G infection may sustain
for a longer period than the other serovars, which would
result in a more common detection of these serovars in
the different populations.29
The present study focused on the diagnosis of urogen-
ital C. trachomatis serovars. However, the RHA typing
assay can also identify the serovars A, B/Ba, C, L1,
L2/L2a, and L3, which are rarely detected in urogenital
samples. Further studies are needed to get more insight
in the prevalence of these serovars in different clinical
samples and to determine the clinical value of
genotyping.
The present Ct-serovar genotyping method aims at the
identification of 3 serogroups and the 14 C. trachomatis
main serovar types. However, in clinical samples, other
genovariants of the serovars may be present that have
not yet been fully characterized. These might result in
aberrant results on the reverse hybridization strip. The
Ct-genotyping RHA step contains serogroup probes and
endogenous plasmid probes, which may serve to identify
novel serovars or genotypes.
The Ct-DT assay can be used to identify new geno-
variants. We detected fewer multiple infections (4% in
The Netherlands and in Uganda) than in Australia (13%)
or Colombia (8.7%).2,30 The difference in detecting mixed
infections might be caused by overestimating the pres-
ence of multiple types as a result of the absence of
probes specific for new variants of C. trachomatis. Seven
Uganda samples showed reactivity to probes for both
serovars H and K, whereas no single infection of either
serovar H or K was observed. Sequence analysis of these
samples revealed presence of a variant of serovar K
(designated K*). However, to classify a sequence as “a
novel genovariant” or serovar, the complete omp1 gene
has to be analyzed to confirm this finding.
The RHA technology offers the possibility for highly
sensitive identification of multiple infections. However,
because our knowledge about genovariants of C. tracho-
matis is still limited, we suggest that mixed infections of
serovars belonging to the same serogroup are verified by
sequence analysis.
The combination of Ct amplification, detection, and
genotyping assay facilitates the detection and identifica-
tion of C. trachomatis serovars and serogroups. The prin-
ciple of screening samples for C. trachomatis with the
DEIA method and further analysis of the positive samples
with the same amplicon for serovar typing offers a rapid
effective method for large epidemiological studies.
Figure 4. Examples of results that were found with the RHA. Table 3 shows
the results after interpretation of the RHA strip (X, unknown).
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